|
|
|
|
|
|
|
|
|
|
|
17.04.26 - 08:54
|
Solar A/S: No. 10 2026 Major shareholder announcement (GlobeNewswire EN)
|
|
|
Pursuant to section 30 of the Danish Capital Markets Act, Solar A/S hereby announces that UBS Group AG has informed Solar that following its sale of shares on 14 April 2026, UBS Group AG's holding of Solar B shares now totals 375,436 shares at DKK 100, corresponding to an ownership share of 4.69%....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17.04.26 - 07:48
|
Carbios announces fiscal-year 2025 financial results (GlobeNewswire EN)
|
|
|
Clermont-Ferrand (France), 17 April 2026 (7:45 am CEST). Carbios (Euronext Growth Paris: ALCRB) today reports operating and financial results for the fiscal-year 2025. The financial statements as of December 31, 2025, were approved by the Company's Board of Directors at their meeting on April 16, 20263....
|
|
|
|
|
17.04.26 - 07:03
|
Dividend Payments ex-date of Coop Pank AS (GlobeNewswire EN)
|
|
|
For the year of 2025 Coop Pank AS will pay dividend in the net amount of 6,5 eurocents per share. The list of shareholders entitled to receive dividend will be established as at 22.04.2026 COB in the settlement system. Consequently, the day of change of the rights related to the shares (ex-date) is set to 21.04.2026. From this day onwards, the person acquiring the shares will not have the right to receive dividend for the financial year 2025. Dividend shall be disbursed to the shareholders on 27.04.2026....
|
|
|
|
|
|
|
|
|
|
|
17.04.26 - 04:45
|
Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock (GlobeNewswire EN)
|
|
|
NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced the pricing of its previously announced underwritten public offering of 11,600,000 shares of its common stock at a public offering price of $13.00 per share, for total proceeds of approximately $150 million, before deducting underwriting discounts and commissions and expenses payable by Trevi. All of the shares in the offering are being sold by Trevi. In addition, Trevi has granted the underwriters a 30-day option to purchase up to 1,740,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about April 20, 202...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
